Literature DB >> 24804745

The mathematician versus the malignancy.

Elie Dolgin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24804745     DOI： 10.1038/nm0514-460

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

1.  Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Authors:  Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

2.  Tumor size, sensitivity to therapy, and design of treatment schedules.

Authors:  L Norton; R Simon
Journal:  Cancer Treat Rep       Date:  1977-10

3.  Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules.

Authors:  Kevin Leder; Ken Pitter; Quincey LaPlant; Dolores Hambardzumyan; Brian D Ross; Timothy A Chan; Eric C Holland; Franziska Michor
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

4.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Authors:  Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.

Authors:  Gianni Bonadonna; Milvia Zambetti; Angela Moliterni; Luca Gianni; Pinuccia Valagussa
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.

Authors:  Jasmine Foo; Juliann Chmielecki; William Pao; Franziska Michor
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

8.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

9.  Adaptive therapy.

Authors:  Robert A Gatenby; Ariosto S Silva; Robert J Gillies; B Roy Frieden
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

10.  Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.

Authors:  Jasmine Foo; Mark W Drummond; Bayard Clarkson; Tessa Holyoake; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2009-09-11       Impact factor: 4.475
View more
  4 in total

Review 1.  Toward a science of tumor forecasting for clinical oncology.

Authors:  Thomas E Yankeelov; Vito Quaranta; Katherine J Evans; Erin C Rericha
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

Review 2.  The war on cancer: a military perspective.

Authors:  Bryan Oronsky; Corey A Carter; Vernon Mackie; Jan Scicinski; Arnold Oronsky; Neil Oronsky; Scott Caroen; Christopher Parker; Michelle Lybeck; Tony Reid
Journal:  Front Oncol       Date:  2015-01-26       Impact factor: 6.244

3.  Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.

Authors:  Satish Sharan; Sukyung Woo
Journal:  Front Pharmacol       Date:  2015-02-20       Impact factor: 5.810

4.  A Perspective on Expanding Our Understanding of Cancer Treatments by Integrating Approaches from the Biological and Physical Sciences.

Authors:  Emma J Fong; Carly Strelez; Shannon M Mumenthaler
Journal:  SLAS Discov       Date:  2020-04-16       Impact factor: 3.341
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.